Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Karydis, Ioannis ^a   Chan, Pui Ying ^b   Wheater, Matthew ^c   Arriola, Edurne ^c   Szlosarek, Peter W ^b,d   Ottensmeier, Christian H ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti PD 1; Immuno oncology; Metastases; Pembrolizumab; Uveal melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IPILIMUMAB; LACTATE DEHYDROGENASE; PEMBROLIZUMAB;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPASSIONATE USE; CUTANEOUS MELANOMA; DIARRHEA; FATIGUE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; IMMUNE RESPONSE; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PANCREAS INSUFFICIENCY; PRURITUS; RADIOFREQUENCY ABLATION; RASH; RETROSPECTIVE STUDY; SJOEGREN SYNDROME; TUMOR ASSOCIATED LEUKOCYTE; UVEA MELANOMA;

EID: 84975804551     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1143997     Document Type: Article

References (27)

1. L.M.Martorano, R.R.Winkelmann, C.M.Cebulla, M.H.Abdel-Rahman, S.M.Campbell. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. Int J Dermatol 2014; 53:657-63; PMID:24697775; http://dx.doi.org/10.1111/ijd.12386
2. S.Papadopoulos, T.Benter, G.Anastassiou, M.Pape, S.Gerhard, N.Bornfeld, W.-D.Ludwig, B.Dörken. Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis. Int J Cancer 2002; 99:193-200; PMID:11979433; http://dx.doi.org/10.1002/ijc.10297
3. L.B.Alexandrov, S.Nik-Zainal, D.C.Wedge, S.A.J.R.Aparicio, S.Behjati, A.V.Biankin, G.R.Bignell, N.Bolli, A.Borg, A.-L.Børresen-Dale et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-21; PMID:23945592; http://dx.doi.org/10.1038/nature12477
4. J.W.Harbour. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res 2012; 25:171-81; PMID:22268848; http://dx.doi.org/10.1111/j.1755-148X.2012.00979.x
5. S.A.Forbes, D.Beare, P.Gunasekaran, K.Leung, N.Bindal, H.Boutselakis, M.Ding, S.Bamford, C.Cole, S.Ward et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43:D805-11; PMID:25355519; http://dx.doi.org/10.1093/nar/gku1075
6. A.Luscan, P.A.Just, A.Briand, C.B.des Roziers, P.Goussard, P.Nitschké, M.Vidaud, M.F.Avril, B.Terris, E.Pasmant. Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes. Br J Ophthalmol 2015; 99:437-9; PMID:25361747; http://dx.doi.org/10.1136/bjophthalmol-2014-305371
7. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol Chic Ill 1960 2005; 123:1639 -43; PMID: 16344433; http://dx.doi.org/10.1001/archopht.123.12.1639
8. D.M.Albert, L.M.Ryan, E.C.Borden. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114:107-8; PMID:8540843; http://dx.doi.org/10.1001/archopht.1996.01100130103030
9. L.E.Flaherty, J.M.Unger, P.Y.Liu, W.C.Mertens, V.K.Sondak. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21:568-72; PMID:9856657; http://dx.doi.org/10.1097/00000421-199812000-00008
10. R.D.Carvajal, J.A.Sosman, J.F.Quevedo, M.M.Milhem, A.M.Joshua, R.R.Kudchadkar, G.P.Linette, T.F.Gajewski, J.Lutzky, D.H.Lawson et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014; 311:2397-405; PMID:24938562; http://dx.doi.org/10.1001/jama.2014.6096
11. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
12. C.Robert, J.Schachter, G.V.Long, A.Arance, J.J.Grob, L.Mortier, A.Daud, M.S.Carlino, C.McNeil, M.Lotem et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
13. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
14. J.D.Wolchok, H.Kluger, M.K.Callahan, M.A.Postow, N.A.Rizvi, A.M.Lesokhin, N.H.Segal, C.E.Ariyan, R.-A.Gordon, K.Reed et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
15. S.Kelderman, M.K.van der Kooij, A.J.M.van den Eertwegh, P.M.M.B.Soetekouw, R.L.H.Jansen, R.R.H.van den Brom, G.A.P.Hospers, J.B.A.G.Haanen, E.Kapiteijn, C.U.Blank. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol 2013; 52:1786-8; PMID:23607756; http://dx.doi.org/10.3109/0284186X.2013.786839
16. M.Maio, R.Danielli, V.Chiarion-Sileni, J.Pigozzo, G.Parmiani, R.Ridolfi, F.D.Rosa, M.D.Vecchio, L.D.Guardo, P.Queirolo et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013; 24:2911-5; PMID:24067719; http://dx.doi.org/10.1093/annonc/mdt376
17. L.Zimmer, J.Vaubel, P.Mohr, A.Hauschild, J.Utikal, J.Simon, C.Garbe, R.Herbst, A.Enk, E.Kämpgen et al. Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. PLoS ONE 2015; 10:e0118564; PMID:25761109; http://dx.doi.org/10.1371/journal.pone.0118564
18. C.D.Van Raamsdonk, K.G.Griewank, M.B.Crosby, M.C.Garrido, S.Vemula, T.Wiesner, A.C.Obenauf, W.Wackernagel, G.Green, N.Bouvier et al. Mutations in GNA11 in Uveal Melanoma. N Engl J Med 2010; 363:2191-9; PMID:21083380; http://dx.doi.org/10.1056/NEJMoa1000584
19. J.A.Errington, R.M.Conway, N.Walsh-Conway, J.Browning, C.Freyer, J.Cebon, M.C.Madigan. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. Br J Ophthalmol 2012; 96:451-8; PMID:22190731; http://dx.doi.org/10.1136/bjophthalmol-2011-300432
20. P.O.L.De Cruz, C.S.Specht, I.W.McLean. Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990; 65:112-5; PMID:2293857; http://dx.doi.org/10.1002/1097-0142(19900101)65:1%3c112::AID-CNCR2820650123%3e3.0.CO;2-X
21. L.A.Kottschade, R.R.McWilliams, S.Markovic, M.S.Block, J.Villasboas Bisneto, A.Q.Pham, R.S.Dronca. The use of pembrolizumab for the treatment of metastatic uveal melanoma. ASCO Meet Abstr 2015; 33:9010
22. J.D.Wolchok, A.Hoos, S.O'Day, J.S.Weber, O.Hamid, C.Lebbé, M.Maio, M.Binder, O.Bohnsack, G.Nichol et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990 2009; 45:228 -47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026
24. Chan T, Wiltrout RH, Weiss JM. Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol 2011; 11:876 -8; PMID: 21241810; http://dx.doi.org/10.1016/j.intimp.2010.12.024
25. S.S.Agarwala, A.M.M.Eggermont, S.O'Day, J.S.Zager. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 2014; 120:781-9; PMID:24301420; http://dx.doi.org/10.1002/cncr.28480
26. M.H.M.G.M.den Brok, R.P.M.Sutmuller, S.Nierkens, E.J.Bennink, C.Frielink, L.W.J.Toonen, O.C.Boerman, C.G.Figdor, T.J.M.Ruers, G.J.Adema. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006; 95:896; PMID:16953240; http://dx.doi.org/10.1038/sj.bjc.6603341
27. Haen SP, Pereira PL, Salih HR, Rammensee H-G, Gouttefangeas C. More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer. Clin Dev Immunol; vol. 2011, Article ID 160250, 19 pages, 2011; PMID: 22242035; http://dx.doi.org/10.1155/2011/160250